Indeed, we also found in these cancers a significant co-occurrence of FGFR3 SVs with CDKN2A/B and TERT, as has been found previously,33 suggesting that it may be possible to stratify patients according to these alterations, but clinical data are required to confirm this hypothesis. The gene discussed is CDKN2A; the disease is cancer.